The invention discloses an application of ergomine in preparation of a
medicine for treating post-traumatic stress disorder caused by
electric shock. According to the method, a post-traumatic stress disorder model is firstly constructed, and the result shows that in post-traumatic stress disorder model animals, remarkable core behavior characteristics such as fear overconsolidation memory and the like are shown. The ergotramine is used for
intervention treatment, so that the fear memory
fading capability of the model animal is obviously improved; behavior experiment comprehensive evaluation shows that the stiffness time of animals in an ergotramine treatment group is remarkably shortened. Experimental results show that the ergotramine can effectively relieve fear
memory disorder of post-traumatic stress disorder model animals. Research finds that when the ergotramine is used for treating mice related to the
electric shock complicated post-traumatic stress disorder, the index of an experimental result is superior to that of
serotonin reuptake inhibitor
medicine sertraline. Related experiments show that the ergotramine has the effect of treating and / or relieving post-traumatic stress disorder and has a good clinical application prospect.